ALTH Allos Therapeutics, Inc. (MM)

Allos Therapeutics Investigator Presents Updated Survival Results From Phase III REACH Study at San Antonio Breast Cancer Symposium WESTMINSTER, Colo., Dec. 9 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (NASDAQ:ALTH) today announced that there will be a presentation on the Company's lead clinical candidate, EFAPROXYN(TM) (efaproxiral), at the Twenty Seventh Annual San Antonio Breast Cancer Symposium taking place December 8 - 11 at the Henry B. Gonzalez Convention Center. Dino B. Stea, M.D., Ph.D., Director, Radiation Oncology at the Arizona Cancer Center, will give a poster presentation titled "Efaproxiral (EFAPROXYN(TM)) as an Adjunct to Whole Brain Radiation Therapy for the Treatment of Brain Metastases Originating from Breast Cancer: updated survival results of the randomized REACH (RT-009) study" on Friday, December 10, 2004, 7:00 AM-9:00 AM. The abstract may be accessed online at http://www.sabcs.org/ at the conclusion of the meeting. About EFAPROXYN EFAPROXYN(TM) (efaproxiral) is the first synthetic small molecule designed to "sensitize" hypoxic (oxygen-deprived) areas of tumors during radiation therapy by facilitating the release of oxygen from hemoglobin, the oxygen-carrying protein contained within red blood cells, and increasing the level of oxygen in tumors. The presence of oxygen in tumors is an essential element for the effectiveness of radiation therapy in the treatment of cancer. By increasing tumor oxygenation at the time of treatment, EFAPROXYN has the potential to enhance the efficacy of standard radiation therapy. Unlike chemotherapeutics or other radiation sensitizers, EFAPROXYN does not have to cross the blood brain barrier or enter the tumor to be effective. About Allos Therapeutics, Inc. Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative drugs for improving cancer treatments. The company's lead clinical candidate, EFAPROXYN, is a synthetic small molecule that has the potential to sensitize hypoxic (oxygen deprived) tumor tissues and enhance the efficacy of standard radiation therapy. In addition, Allos is developing PDX (pralatrexate), a novel small molecule cytoxic injectable antifolate (DHFR inhibitor) that is currently being investigated in patients with non-small cell lung cancer and non-Hodgkin's lymphoma. For more information, please visit the company's web site at: http://www.allos.com/. Safe Harbor Statement This announcement contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements concerning the Company's business plans, objectives, goals and strategies; the Company's product development plans and activities; the anticipated timing, progress and results of the Company's clinical trials; the potential safety and efficacy of the Company's product candidates; the potential market opportunity for the Company's product candidates; and other statements which are other than statements of historical facts. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "continue," and other similar terminology or the negative of these terms, but their absence does not mean that a particular statement is not forward-looking. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated by these forward-looking statements. Additional information concerning the risks and uncertainties that may cause such differences is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2003, as amended, and in the Company's other periodic reports and filings with the Securities and Exchange Commission, including the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2004. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this announcement. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this announcement, except as required by law. DATASOURCE: Allos Therapeutics, Inc. CONTACT: Jennifer Neiman, Manager, Corporate Communications of Allos Therapeutics, +1-720-540-5227, Web site: http://www.sabcs.org/ Web site: http://www.allos.com/

Copyright